ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', 'biontech']
biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco 
The latest news about the biotech and pharmaceutical industy.